Cris Loiren Rodriguez

Array ( [id] => 8670729 [patent_doc_number] => 20130045267 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-21 [patent_title] => 'METHODS OF USING AGENTS THAT MODULATE CLAUDIN EXPRESSION' [patent_app_type] => utility [patent_app_number] => 13/576959 [patent_app_country] => US [patent_app_date] => 2011-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 26987 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13576959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8606101 [patent_doc_number] => 20130011413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-10 [patent_title] => 'Method and Pharmaceutical Composition for Treatment of Intestinal Disease' [patent_app_type] => utility [patent_app_number] => 13/575949 [patent_app_country] => US [patent_app_date] => 2011-02-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 14918 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13575949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8398397 [patent_doc_number] => 08268773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-09-18 [patent_title] => 'Methods of treating multiple sclerosis (MS) using an IL-17A and IL-17F antagonist' [patent_app_type] => utility [patent_app_number] => 13/015304 [patent_app_country] => US [patent_app_date] => 2011-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59242 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13015304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5944954 [patent_doc_number] => 20110105574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-05 [patent_title] => 'PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS' [patent_app_type] => utility [patent_app_number] => 13/006984 [patent_app_country] => US [patent_app_date] => 2011-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 5845 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0105/20110105574.pdf [firstpage_image] =>[orig_patent_app_number] => 13006984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10856958 [patent_doc_number] => 08883151 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-11-11 [patent_title] => 'IL-17 receptor antibody formulation' [patent_app_type] => utility [patent_app_number] => 13/521999 [patent_app_country] => US [patent_app_date] => 2011-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 16 [patent_no_of_words] => 124506 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13521999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6174018 [patent_doc_number] => 20110177022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-21 [patent_title] => 'Mammalian Cytokines; Related Reagents and Methods' [patent_app_type] => utility [patent_app_number] => 12/984523 [patent_app_country] => US [patent_app_date] => 2011-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25269 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0177/20110177022.pdf [firstpage_image] =>[orig_patent_app_number] => 12984523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6159310 [patent_doc_number] => 20110158938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-30 [patent_title] => 'IL-15 BINDING SITE FOR IL 15-RALPHA AND SPECIFIC IL-15 MUTANTS HAVING AGONISTS / ANTAGONISTS ACTIVITY' [patent_app_type] => utility [patent_app_number] => 12/978115 [patent_app_country] => US [patent_app_date] => 2010-12-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 13468 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0158/20110158938.pdf [firstpage_image] =>[orig_patent_app_number] => 12978115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8339707 [patent_doc_number] => 08241629 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-08-14 [patent_title] => 'Anti-human IL-21 monoclonal antibodies' [patent_app_type] => utility [patent_app_number] => 12/971495 [patent_app_country] => US [patent_app_date] => 2010-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 38574 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12971495 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18603437 [patent_doc_number] => 11744877 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-05 [patent_title] => Method for permeabilizing tumor vasculature using a tumor vasculature permeabilizing molecule to improve access of a therapeutic or diagnostic agent to a tumor [patent_app_type] => utility [patent_app_number] => 13/514138 [patent_app_country] => US [patent_app_date] => 2010-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 4 [patent_no_of_words] => 17764 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13514138 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6083585 [patent_doc_number] => 20110144008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'PEPTIDE AGONISTS OF GLP-1 ACTIVITY' [patent_app_type] => utility [patent_app_number] => 12/957916 [patent_app_country] => US [patent_app_date] => 2010-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 28958 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0144/20110144008.pdf [firstpage_image] =>[orig_patent_app_number] => 12957916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6024844 [patent_doc_number] => 20110053170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-03 [patent_title] => 'Interleukin-33 (IL-33) for the Diagnosis and Prognosis of Cardiovascular Disease' [patent_app_type] => utility [patent_app_number] => 12/943676 [patent_app_country] => US [patent_app_date] => 2010-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4743 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0053/20110053170.pdf [firstpage_image] =>[orig_patent_app_number] => 12943676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9620474 [patent_doc_number] => 08790643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-07-29 [patent_title] => 'Methods for treating disease using an anti-IL-21 receptor antibody' [patent_app_type] => utility [patent_app_number] => 12/941354 [patent_app_country] => US [patent_app_date] => 2010-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20940 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12941354 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6189797 [patent_doc_number] => 20110172154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-07-14 [patent_title] => 'PREVENTIVE AND/OR THERAPEUTIC AND/OR AGGRAVATION SUPPRESSING AGENT FOR HUMAN ARTHRITIS DEFORMANS' [patent_app_type] => utility [patent_app_number] => 12/940380 [patent_app_country] => US [patent_app_date] => 2010-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7572 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0172/20110172154.pdf [firstpage_image] =>[orig_patent_app_number] => 12940380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8370180 [patent_doc_number] => 20120219565 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-30 [patent_title] => 'ENGINEERED ANTI-TSLP ANTIBODY' [patent_app_type] => utility [patent_app_number] => 13/505340 [patent_app_country] => US [patent_app_date] => 2010-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 18380 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13505340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8995222 [patent_doc_number] => 08519107 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-08-27 [patent_title] => 'IL-17A antibodies' [patent_app_type] => utility [patent_app_number] => 12/915445 [patent_app_country] => US [patent_app_date] => 2010-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 30 [patent_no_of_words] => 20954 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12915445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8509159 [patent_doc_number] => 20120308566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-12-06 [patent_title] => 'USE OF IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 13/501430 [patent_app_country] => US [patent_app_date] => 2010-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 21 [patent_no_of_words] => 87266 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13501430 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8707499 [patent_doc_number] => 20130064788 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-14 [patent_title] => 'IL-17 FAMILY CYTOKINE COMPOSITIONS AND USES' [patent_app_type] => utility [patent_app_number] => 13/501244 [patent_app_country] => US [patent_app_date] => 2010-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 31971 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13501244 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001481 [patent_doc_number] => 09045559 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-06-02 [patent_title] => 'Method for screening inhibitors of interleukin-32 (IL-32)' [patent_app_type] => utility [patent_app_number] => 12/900870 [patent_app_country] => US [patent_app_date] => 2010-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14263 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12900870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6148785 [patent_doc_number] => 20110020380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-27 [patent_title] => 'Human Tumor Necrosis Factor TR18 and Methods Based Thereon' [patent_app_type] => utility [patent_app_number] => 12/892534 [patent_app_country] => US [patent_app_date] => 2010-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 111235 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0020/20110020380.pdf [firstpage_image] =>[orig_patent_app_number] => 12892534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8713489 [patent_doc_number] => 08399629 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-03-19 [patent_title] => 'Antibody modulators of hepatocyte growth factor activator' [patent_app_type] => utility [patent_app_number] => 12/883033 [patent_app_country] => US [patent_app_date] => 2010-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 31721 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12883033 [rel_patent_id] =>[rel_patent_doc_number] =>)